On Feb 04, 2026, NVS reported earnings of 2.02 USD per share (EPS) for Q4 25, beating the estimate of 2.02 USD, resulting in a 0.27% surprise. Revenue reached 13.34 billion, compared to an expected 14.00 billion, with a -4.73% difference. The market reacted with a +2.04% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of 2.27 USD, with revenue projected to reach 14.00 billion USD, implying an increase of 12.38% EPS, and increase of 4.96% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Eli Lilly & Co.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$6.73
Actual
$7.54
Surprise
+11.92%
ABBVIE INC.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$2.70
Actual
$2.71
Surprise
+0.17%
Merck & Co., Inc.
Report Date
Feb 03, 2026 For Q4 25
Estimate
$2.02
Actual
$2.04
Surprise
+0.52%
Novo-Nordisk A/S
Report Date
Feb 04, 2026 For Q4 25
Estimate
$5.97
Actual
$6.32
Surprise
+5.77%
Pfizer Inc.
Report Date
Feb 03, 2026 For Q4 25
Estimate
$0.57
Actual
$0.66
Surprise
+14.29%
Sanofi - ADR
Report Date
Jan 29, 2026 For Q4 25
Estimate
$1.46
Actual
$1.53
Surprise
+4.22%
FAQ
What were Novartis AG's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Novartis AG reported EPS of $2.02, missing estimates by 0.27%, and revenue of $13.34B, -4.73% below expectations.
How did the market react to Novartis AG's Q4 2025 earnings?
The stock price moved up 2.04%, changed from $149.86 before the earnings release to $152.91 the day after.
When is Novartis AG expected to report next?
The next earning report is scheduled for Apr 27, 2026.
What are the forecasts for Novartis AG's next earnings report?
Based on 4
analysts, Novartis AG is expected to report EPS of $2.27 and revenue of $14.00B for Q1 2026.